I'm LongbridgeAI, I can summarize articles.DCOY.US lost 17.09% this week to close at $0.97, down from $1.17 the previous Friday. The S&P 500 fell 0.47% over the same period, leaving the stock about 16.62 percentage points behind the benchmark. The week was a steady slide: Monday opened at $1.19, Tuesday slipped below $1.15, Wednesday touched $1.037, Thursday closed at $1.03, and Friday printed a low of $0.96 before finishing at $0.97. The weekly range was 19.33% wide, with average daily volume running 32.58% above its median.
The Week
DCOY.US lost 17.09% this week to close at $0.97, down from $1.17 the previous Friday. The S&P 500 fell 0.47% over the same period, leaving the stock about 16.62 percentage points behind the benchmark. The week was a steady slide: Monday opened at $1.19, Tuesday slipped below $1.15, Wednesday touched $1.037, Thursday closed at $1.03, and Friday printed a low of $0.96 before finishing at $0.97. The weekly range was 19.33% wide, with average daily volume running 32.58% above its median.
Key Events
The only material filing this week came on Monday, when Decoy Therapeutics submitted an EFFECT notice, a routine effectiveness disclosure. On the news side, a Tuesday piece grouped Decoy among small-caps discussed as ‘dividend aristocrats in disguise’, while a Friday pre-market note flagged the stock hitting a fresh 52-week low near $1.00 before it drifted lower through the session. No new product, earnings, or regulatory news surfaced during the week, leaving the price under pressure alongside small-caps generally.
Analyst Ratings
One analyst covers the stock, with a buy rating. The consensus rating is strong buy, and the consensus target sits at $3.00, about 209.28% above the latest price of $0.97. The high and low targets are both $3.00, pointing to no dispersion across the single covering desk. Within the biotechnology industry of 511 names, Decoy ranks 507th by analyst rating coverage.
The Week Ahead
Macro data dominate the next few sessions: Monday brings the Dallas Fed manufacturing business activity index, while Tuesday sees durable goods orders, FHFA house prices, the Case Shiller 20-city index, new home sales, the Richmond Fed composite index, and consumer confidence. On the company side, Decoy Therapeutics is scheduled to report fiscal Q3 2026 earnings after market close on 10 November, with consensus EPS estimated at -$2.59.
In Short
This week pitched a strong-buy consensus and a $3 target against a price that broke below $1 and made a fresh 52-week low. The latest session also showed net selling from medium and small orders. The PB ratio sits near 0.15x with a negative PE, so the book value looks low while fundamentals remain weak. The gap between the consensus target and the spot price will likely stay in focus until the 10 November quarterly report.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.